PriceTargets.com logo

VanEck Bionic Engineering UCITS ETF A Acc - CYBG Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 17.08 As of 04/19/2024 05:16 PM ET
▲ +0.033 (0.19%)

This chart shows the closing price for CYBG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VanEck Bionic Engineering UCITS ETF A Acc Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYBG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYBG

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for VanEck Bionic Engineering UCITS ETF A Acc in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 17.08.

This chart shows the closing price for CYBG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in VanEck Bionic Engineering UCITS ETF A Acc. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/22/2019HSBCInitiated CoverageBuyGBX 160
10/17/2019Deutsche Bank AktiengesellschaftReiterated RatingHold
10/14/2019BarclaysReiterated RatingEqual weight
10/14/2019Jefferies Financial GroupLower TargetBuyGBX 341 ➝ GBX 189
10/1/2019BarclaysLower TargetEqual WeightGBX 180 ➝ GBX 145
9/13/2019Shore CapitalReiterated RatingBuy
9/6/2019JPMorgan Chase & Co.Lower TargetNeutralGBX 200 ➝ GBX 150
9/6/2019Deutsche Bank AktiengesellschaftLower TargetHoldGBX 220 ➝ GBX 180
9/6/2019CitigroupReiterated RatingBuyGBX 180
9/5/2019UBS GroupReiterated RatingBuyGBX 170 ➝ GBX 155
8/29/2019Royal Bank of CanadaReiterated RatingOutperformGBX 250 ➝ GBX 210
8/19/2019UBS GroupUpgradeBuyGBX 195 ➝ GBX 170
8/15/2019The Goldman Sachs GroupLower TargetNeutralGBX 250 ➝ GBX 215
7/31/2019Deutsche Bank AktiengesellschaftReiterated RatingHold
7/30/2019Jefferies Financial GroupReiterated RatingBuyGBX 341
7/30/2019Shore CapitalReiterated RatingBuy
7/29/2019UBS GroupReiterated RatingNeutral
7/26/2019Morgan StanleyBoost TargetEqual weightGBX 200 ➝ GBX 205
7/24/2019Deutsche Bank AktiengesellschaftBoost TargetHoldGBX 214 ➝ GBX 220
7/17/2019BarclaysReiterated RatingEqual weight
7/12/2019Deutsche Bank AktiengesellschaftLower TargetHoldGBX 215 ➝ GBX 214
7/1/2019Jefferies Financial GroupBoost TargetBuyGBX 285 ➝ GBX 341
6/21/2019CitigroupReiterated RatingBuyGBX 245
6/21/2019BarclaysBoost TargetEqual WeightGBX 200 ➝ GBX 210
6/20/2019UBS GroupReiterated RatingNeutralGBX 188 ➝ GBX 195
6/20/2019Royal Bank of CanadaReiterated RatingOutperformGBX 250
6/19/2019Shore CapitalReiterated RatingBuyGBX 280 ➝ GBX 265
6/5/2019Morgan StanleyLower TargetEqual WeightGBX 235 ➝ GBX 200
5/23/2019The Goldman Sachs GroupLower TargetNeutralGBX 260 ➝ GBX 250
5/10/2019UBS GroupReiterated RatingNeutral
4/23/2019UBS GroupBoost TargetNeutralGBX 193 ➝ GBX 201
(Data available from 4/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
VanEck Bionic Engineering UCITS ETF A Acc logo
CYBG PLC, through its subsidiaries, provides retail and business banking products and services to individuals and businesses under the Clydesdale Bank, Yorkshire Bank, B, and Virgin Money brands in the United Kingdom. It operates through SME Banking and Retail Banking segments. The SME Banking segment offers a range of banking products and services, including business current accounts; and secured and unsecured term loans, business overdrafts, and invoice and asset financing products and services. It also provides international trade services, such as import loans, export loans, documentary collections, currency guarantees, and letters of credit for securing trade; and current account facilities comprising debit cards, cheque books, regular statements, direct debits, and standing orders, as well as day to day and online banking services. This segment serves business customers in the small business, commercial, corporate, and structured finance markets. The Retail Banking segment offers personal current accounts, savings accounts, and term deposits; occupied mortgage loans and BTL loans, unsecured personal loans, and overdrafts, as well as credit card products; and insurance and investment products. The company was founded in 1838 and is based in Leeds, the United Kingdom.
Read More

Today's Range

Now: GBX 17.08
Low: 17.08
High: 17.08

50 Day Range

MA: GBX 17.13
Low: 16.53
High: 17.73

52 Week Range

Now: GBX 17.08
Low: 13.47
High: 18.36

Volume

219 shs

Average Volume

336 shs

Market Capitalization

£244.95 million

P/E Ratio

N/A

Dividend Yield

2.25%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of VanEck Bionic Engineering UCITS ETF A Acc?

The following Wall Street sell-side analysts have issued reports on VanEck Bionic Engineering UCITS ETF A Acc in the last twelve months:
View the latest analyst ratings for CYBG.

What is the current price target for VanEck Bionic Engineering UCITS ETF A Acc?

0 Wall Street analysts have set twelve-month price targets for VanEck Bionic Engineering UCITS ETF A Acc in the last year. has the lowest price target set, forecasting a price of £100,000 for VanEck Bionic Engineering UCITS ETF A Acc in the next year.
View the latest price targets for CYBG.

What is the current consensus analyst rating for VanEck Bionic Engineering UCITS ETF A Acc?

VanEck Bionic Engineering UCITS ETF A Acc currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYBG.

What other companies compete with VanEck Bionic Engineering UCITS ETF A Acc?

Other companies that are similar to VanEck Bionic Engineering UCITS ETF A Acc include Charter Court Financial Services Grp, Witan Pacific Investment Trust PLC (WPC.L), JPMorgan European Investment Trust Income Pool, McKay Securities and JP Morgan Chinese Investment Trust. Learn More about companies similar to VanEck Bionic Engineering UCITS ETF A Acc.

How do I contact VanEck Bionic Engineering UCITS ETF A Acc's investor relations team?

VanEck Bionic Engineering UCITS ETF A Acc's physical mailing address is 51 West George St, 40 St. Vincent Place, GLASGOW, G1 2HL, United Kingdom. The company's listed phone number is +44-141-2324763. The official website for VanEck Bionic Engineering UCITS ETF A Acc is www.cybg.com. Learn More about contacing VanEck Bionic Engineering UCITS ETF A Acc investor relations.